Elevance Health, Inc. $ELV Shares Sold by Mitsubishi UFJ Trust & Banking Corp

Mitsubishi UFJ Trust & Banking Corp reduced its position in Elevance Health, Inc. (NYSE:ELV) by 35.7% in the 4th quarter, Holdings Channel reports. The firm owned 184,120 shares of the company’s stock after selling 102,131 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Elevance Health were worth $64,543,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Sei Investments Co. grew its position in Elevance Health by 7.7% during the second quarter. Sei Investments Co. now owns 163,668 shares of the company’s stock worth $63,666,000 after buying an additional 11,745 shares during the period. Glenview Trust co lifted its holdings in shares of Elevance Health by 41.5% in the second quarter. Glenview Trust co now owns 1,619 shares of the company’s stock valued at $630,000 after purchasing an additional 475 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in shares of Elevance Health by 6.9% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 65,945 shares of the company’s stock valued at $25,650,000 after purchasing an additional 4,272 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Elevance Health by 5.0% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 42,371 shares of the company’s stock valued at $16,478,000 after purchasing an additional 2,012 shares in the last quarter. Finally, Quantinno Capital Management LP lifted its holdings in shares of Elevance Health by 111.8% in the second quarter. Quantinno Capital Management LP now owns 43,911 shares of the company’s stock valued at $17,080,000 after purchasing an additional 23,180 shares in the last quarter. 89.24% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on ELV shares. Robert W. Baird upped their price target on shares of Elevance Health from $317.00 to $331.00 and gave the company a “neutral” rating in a report on Thursday, April 23rd. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Elevance Health from $332.00 to $363.00 and gave the company a “hold” rating in a research report on Thursday, April 23rd. Leerink Partners set a $364.00 price objective on shares of Elevance Health in a research report on Thursday, April 23rd. The Goldman Sachs Group boosted their price objective on shares of Elevance Health from $350.00 to $370.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Elevance Health from $397.00 to $411.00 and gave the company an “overweight” rating in a research report on Tuesday. Eleven analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $381.16.

Elevance Health Trading Up 1.8%

ELV opened at $362.66 on Wednesday. The firm has a market capitalization of $78.75 billion, a P/E ratio of 15.43, a P/E/G ratio of 2.13 and a beta of 0.49. The firm’s 50 day moving average is $309.52 and its 200-day moving average is $331.28. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $424.24. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company had revenue of $49.49 billion for the quarter, compared to analyst estimates of $48.21 billion. During the same quarter last year, the firm posted $11.97 earnings per share. The business’s quarterly revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Analysts expect that Elevance Health, Inc. will post 26.79 EPS for the current fiscal year.

Elevance Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be issued a dividend of $1.72 per share. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.9%. Elevance Health’s payout ratio is currently 29.26%.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.